Privosegtor Receives Breakthrough Drug Designation - Summary - MDSpire

Privosegtor Receives Breakthrough Drug Designation

In a phase 2 trial, the drug showed functional and structural signals in optic neuritis.

  • By

  • Conexiant News Staff

  • January 6, 2026

  • 2 min

Share

Objective:

To report on the FDA granting breakthrough therapy designation to Privosegtor for treating optic neuritis.

Key Findings:
  • Patients receiving Privosegtor gained an average of 18 letters on the ETDRS low-contrast visual acuity chart at 3 months.
  • The trial demonstrated preservation of retinal and optic nerve structure and reduced neurofilament release.
  • Common adverse events included headache and acne, with no serious drug-related events reported.
Interpretation:

The breakthrough designation highlights the potential of Privosegtor as a significant advancement in treating optic neuritis.

Limitations:
  • The study's sample size and duration may limit the generalizability of the findings.
  • Long-term effects and efficacy in broader populations remain to be established.
Conclusion:

Oculis is advancing the PIONEER program with pivotal trials to support the registration of Privosegtor for optic neuritis and related conditions.

Original Source(s)

Privosegtor Receives Breakthrough Drug Designation

  • by Conexiant News Staff

  • January 6, 2026

Related Content

Osteoporosis Linked to Increased Dry AMD Risk

Genetic and pooled observational data suggest a unidirectional association, with elevated odds of dry age-related macular degeneration and a stronger signal in women.

Retinal Age as Disease Biomarker

Fundus-based AI screening can indicate “retinal age” of patients, as well as flag systemic disease risks, says new study

  • May 27, 2026

  • 3 min
Floaters May Signal Higher Risk Than Flashes

New study examines retinal detachment risk in primary care presentations